The case for & against
Bull & Bear analysis
Bullish
IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a global leader in veterinary diagnostics and software solutions aimed at enhancing pet healthcare. With a strong focus on companion animal health, IDEXX encompasses advanced diagnostic technologies to support veterinary practices’ operational efficiencies. Positioned favorably within a booming pet care industry, the company harnesses data, innovation, and technology to drive sustainable growth amid evolving market trends and increasing demand for pet diagnostics.
Bull says
- ↑Q1 revenue rose 14% to $1.3 B, with 11% organic growth
- ↑EBITDA margin expanded to 32.3% on operational efficiency gains
- ↑Free cash flow of $234 M in Q1, 99% net income conversion
- ↑International diagnostics up 12% organically, driving global expansion
- ↑Raised FY26 revenue guide to $4.675–4.76 B on new tech rollouts
- ↑High profitability and consistent growth revisions support valuation
Bear says
- ↓U.S. same-store clinical visits fell 1%, pressuring wellness revenue
- ↓Negative earnings yield signals weak return on capital
- ↓Book-to-price ratio premium raises valuation concerns
- ↓Growth hinges on market adoption of new products like InView DX
- ↓Intensifying diagnostics competition may compress margins
- ↓Foreign exchange and interest-rate sensitivity pose additional headwinds
Investment themes with IDXX
Quality↑ +0.54%
Companies with strong fundamentals and stability
NVDA · AAPL · MSFT
Medical Devices↑ +0.12%
Devices and instruments for medical treatment
ISRG · ABT · SYK
Pets↑ +0.12%
Products and services for pet owners
CHWY · FRPT · IDXX
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-09-2026neutral
Transcript signals
Bull points
- I see a meaningful opportunity ahead to further accelerate our innovation-driven platform growth strategy.
- We will also continue to advance commercial reach through investments to expand our field-based presence in key geographies around the world.
- I see advancements in AI as incredibly promising to further accelerate our innovation, expand testing access and utilization, and drive deeper patient-level insights.
Bear points
- CAG diagnostic recurring revenue growth in Q1 was negatively impacted by declines in U.S. same-store clinical visits of approximately 1%, with slightly positive growth in non-well visits, more than offset by pressure on wellness visits.
- U.S. clinical visits to a decline of minus 1.5%, after a third sequential quarter of clinical visits trending between minus 1 to minus 2% and aligned with the trailing 12-month average.
- U.S. clinical visit growth in line with the full year estimate.
Read full transcript analysis ›